---
document_datetime: 2025-12-02 05:04:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/casgevy.html
document_name: casgevy.html
version: success
processing_time: 0.3612454
conversion_datetime: 2025-12-25 06:20:31.181137
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Casgevy

[RSS](/en/individual-human-medicine.xml/91355)

##### Authorised

This medicine is authorised for use in the European Union

exagamglogene autotemcel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Casgevy](#news-on)
- [More information on Casgevy](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older.

For beta thalassaemia, Casgevy is used in patients who require regular blood transfusions. Patients with this condition do not make enough haemoglobin, the protein in red blood cells that carries oxygen around the body. As a result, these patients have low red blood cell levels and need frequent blood transfusions.

For sickle cell disease, Casgevy is used in patients with severe disease and recurrent painful crises. Patients with this condition have an abnormal form of haemoglobin that makes red blood cells become rigid and sticky and change from being disc-shaped to being crescent-shaped (like a sickle). These cells can block blood vessels, causing painful crises that affect the chest, abdomen (belly) and other parts of the body.

Beta thalassaemia and sickle cell disease are rare, and Casgevy was designated an 'orphan medicine' (a medicine used in rare diseases). Further information on the orphan designations can be found on the European Medicine's Agency website ( [beta thalassaemia](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2210) : 17 October 2019; [sickle cell disease](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2242) : 9 January 2020)

Casgevy contains as its active substance genetically modified stem cells (cells that can develop into blood cells) taken from the patient's own blood. It is used when stem cell treatments are appropriate and there are no suitable stem cell donors available.

Expand section

Collapse section

## How is Casgevy used?

Casgevy can only be obtained with a prescription and must be given in an approved centre by a doctor trained in giving this medicine and who has experience in stem cell transplantation and in the treatment of blood disorders affecting haemoglobin.

Casgevy is made individually for each patient out of stem cells collected from their blood and must only be given to the patient for whom it is made. It is given as a single dose infusion (drip) into a vein and the dose depends on the bodyweight of the patient.

Before Casgevy is given, the patient will receive conditioning chemotherapy treatment to clear their bone marrow of cells.

For more information about using Casgevy, see the package leaflet or contact your healthcare provider.

## How does Casgevy work?

To make Casgevy, stem cells are edited (by CRISPR/Cas9 technology) so that they produce more fetal haemoglobin, a type of haemoglobin mainly found in babies in the womb but also present in small amounts in adults. Because fetal haemoglobin can compensate for the lack of normal adult haemoglobin, the modified stem cells, when injected into patients, can raise red blood cell levels in patients with beta-thalassaemia and prevent painful crises in patients with sickle cell disease.

## What benefits of Casgevy have been shown in studies?

The effects of Casgevy are based on interim results of two studies which are still ongoing. The studies did not compare Casgevy to another medicine or placebo.

In one study in patients with thalassaemia aged between 12 and 35 years where the medicine was given after conditioning chemotherapy treatment, 39 patients out of 42 maintained haemoglobin levels above 9 g/dL without the need for blood transfusions for at least 12 consecutive months.

Casgevy was also shown to be effective at preventing painful sickle cell crises. In a study in patients with severe sickle cell disease aged between 12 and 35 years, 28 out of 29 patients did not experience any painful crises for at least 12 consecutive months when treated with Casgevy after conditioning chemotherapy. None of the patients (29 out of 29) required hospitalisation for painful crises for at least 12 consecutive months.

## What are the risks associated with Casgevy?

For the full list of side effects and restrictions with Casgevy, see the package leaflet.

The most common side effects with Casgevy (which may affect more than 1 in 10 people) include headache, nausea (sickness) and muscle and bone pain.

Doctors should consider whether patients can be given the required pre-treatments needed before Casgevy.

## Why is Casgevy authorised in the EU?

Beta thalassaemia requiring transfusions and sickle cell disease are serious conditions for which treatment options are limited. Although the studies with Casgevy were small and there were uncertainties associated with their design they showed that one-time treatment can reduce the need for red blood cell transfusions in patients with beta-thalassaemia and reduce the number of painful crises in patients with sickle cell disease.

In terms of safety, treatment was generally well tolerated and side effects were mainly due to the conditioning chemotherapy. There could be a theoretical risk of cancer caused by unintended changes in the genetic material, although no such cases have been seen so far. There is also a potential risk of bleeding since the medicine may cause a drop in the number of platelets (components that help the blood to clot). Measures are in place to monitor for such events through a 15 year registry-based study.

The European Medicines Agency decided that Casgevy's benefits are greater than its risks and it can be authorised for use in the EU. Casgevy has been given 'conditional authorisation'. This means that that the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the Agency will review any new information that becomes available until data become comprehensive and this overview will be updated as necessary.

## What measures are being taken to ensure the safe and effective use of Casgevy?

The company that markets Casgevy will provide results of ongoing studies to further assess the effectiveness and safety of the medicine. The company will also provide educational materials for healthcare professionals expected to use the medicine with information on its safety, including the potential risk of cancer and the need to monitor the patient's platelet levels, and how the medicine should be given. Patients will also receive a guide and a card that they should carry with them.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Casgevy have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Casgevy are continuously monitored. Suspected side effects reported with Casgevy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Casgevy

Casgevy received a conditional marketing authorisation valid throughout the EU on 9 February 2024.

Casgevy : EPAR - Medicine overview

Reference Number: EMA/56648/2024

English (EN) (119.25 KB - PDF)

**First published:** 28/02/2024

[View](/en/documents/overview/casgevy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-933)

български (BG) (136.14 KB - PDF)

**First published:**

28/02/2024

[View](/bg/documents/overview/casgevy-epar-medicine-overview_bg.pdf)

español (ES) (120.74 KB - PDF)

**First published:**

28/02/2024

[View](/es/documents/overview/casgevy-epar-medicine-overview_es.pdf)

čeština (CS) (133.16 KB - PDF)

**First published:**

28/02/2024

[View](/cs/documents/overview/casgevy-epar-medicine-overview_cs.pdf)

dansk (DA) (108.99 KB - PDF)

**First published:**

28/02/2024

[View](/da/documents/overview/casgevy-epar-medicine-overview_da.pdf)

Deutsch (DE) (113.9 KB - PDF)

**First published:**

28/02/2024

[View](/de/documents/overview/casgevy-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.79 KB - PDF)

**First published:**

28/02/2024

[View](/et/documents/overview/casgevy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (137.04 KB - PDF)

**First published:**

28/02/2024

[View](/el/documents/overview/casgevy-epar-medicine-overview_el.pdf)

français (FR) (110.07 KB - PDF)

**First published:**

28/02/2024

[View](/fr/documents/overview/casgevy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (131.53 KB - PDF)

**First published:**

28/02/2024

[View](/hr/documents/overview/casgevy-epar-medicine-overview_hr.pdf)

italiano (IT) (107.82 KB - PDF)

**First published:**

28/02/2024

[View](/it/documents/overview/casgevy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (156.56 KB - PDF)

**First published:**

28/02/2024

[View](/lv/documents/overview/casgevy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (130.6 KB - PDF)

**First published:**

28/02/2024

[View](/lt/documents/overview/casgevy-epar-medicine-overview_lt.pdf)

magyar (HU) (132.03 KB - PDF)

**First published:**

28/02/2024

[View](/hu/documents/overview/casgevy-epar-medicine-overview_hu.pdf)

Malti (MT) (143.61 KB - PDF)

**First published:**

28/02/2024

[View](/mt/documents/overview/casgevy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (110.35 KB - PDF)

**First published:**

28/02/2024

[View](/nl/documents/overview/casgevy-epar-medicine-overview_nl.pdf)

polski (PL) (136.19 KB - PDF)

**First published:**

28/02/2024

[View](/pl/documents/overview/casgevy-epar-medicine-overview_pl.pdf)

português (PT) (109.37 KB - PDF)

**First published:**

28/02/2024

[View](/pt/documents/overview/casgevy-epar-medicine-overview_pt.pdf)

română (RO) (128.24 KB - PDF)

**First published:**

28/02/2024

[View](/ro/documents/overview/casgevy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (133.78 KB - PDF)

**First published:**

28/02/2024

[View](/sk/documents/overview/casgevy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.01 KB - PDF)

**First published:**

28/02/2024

[View](/sl/documents/overview/casgevy-epar-medicine-overview_sl.pdf)

Suomi (FI) (105.85 KB - PDF)

**First published:**

28/02/2024

[View](/fi/documents/overview/casgevy-epar-medicine-overview_fi.pdf)

svenska (SV) (106.86 KB - PDF)

**First published:**

28/02/2024

[View](/sv/documents/overview/casgevy-epar-medicine-overview_sv.pdf)

Casgevy : EPAR - Risk management plan

English (EN) (4.04 MB - PDF)

**First published:** 28/02/2024

[View](/en/documents/rmp/casgevy-epar-risk-management-plan_en.pdf)

## Product information

Casgevy : EPAR - Product information

English (EN) (961.79 KB - PDF)

**First published:** 28/02/2024

**Last updated:** 03/09/2025

[View](/en/documents/product-information/casgevy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-100)

български (BG) (1.12 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/bg/documents/product-information/casgevy-epar-product-information_bg.pdf)

español (ES) (961.58 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/es/documents/product-information/casgevy-epar-product-information_es.pdf)

čeština (CS) (900.05 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/cs/documents/product-information/casgevy-epar-product-information_cs.pdf)

dansk (DA) (1.02 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/da/documents/product-information/casgevy-epar-product-information_da.pdf)

Deutsch (DE) (846.55 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/de/documents/product-information/casgevy-epar-product-information_de.pdf)

eesti keel (ET) (992.22 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/et/documents/product-information/casgevy-epar-product-information_et.pdf)

ελληνικά (EL) (1 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/el/documents/product-information/casgevy-epar-product-information_el.pdf)

français (FR) (749.53 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/fr/documents/product-information/casgevy-epar-product-information_fr.pdf)

hrvatski (HR) (842.33 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/hr/documents/product-information/casgevy-epar-product-information_hr.pdf)

íslenska (IS) (959.04 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/is/documents/product-information/casgevy-epar-product-information_is.pdf)

italiano (IT) (903.63 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/it/documents/product-information/casgevy-epar-product-information_it.pdf)

latviešu valoda (LV) (922.02 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/lv/documents/product-information/casgevy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.03 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/lt/documents/product-information/casgevy-epar-product-information_lt.pdf)

magyar (HU) (1001.62 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/hu/documents/product-information/casgevy-epar-product-information_hu.pdf)

Malti (MT) (1.07 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/mt/documents/product-information/casgevy-epar-product-information_mt.pdf)

Nederlands (NL) (1.06 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/nl/documents/product-information/casgevy-epar-product-information_nl.pdf)

norsk (NO) (968.52 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/no/documents/product-information/casgevy-epar-product-information_no.pdf)

polski (PL) (1.14 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/pl/documents/product-information/casgevy-epar-product-information_pl.pdf)

português (PT) (862.5 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/pt/documents/product-information/casgevy-epar-product-information_pt.pdf)

română (RO) (1 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/ro/documents/product-information/casgevy-epar-product-information_ro.pdf)

slovenčina (SK) (880.73 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/sk/documents/product-information/casgevy-epar-product-information_sk.pdf)

slovenščina (SL) (1.01 MB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/sl/documents/product-information/casgevy-epar-product-information_sl.pdf)

Suomi (FI) (793.29 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/fi/documents/product-information/casgevy-epar-product-information_fi.pdf)

svenska (SV) (995.04 KB - PDF)

**First published:**

28/02/2024

**Last updated:**

03/09/2025

[View](/sv/documents/product-information/casgevy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000258214 24/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Casgevy : EPAR - All authorised presentations

English (EN) (69.75 KB - PDF)

**First published:** 28/02/2024

[View](/en/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-43)

български (BG) (81.42 KB - PDF)

**First published:**

28/02/2024

[View](/bg/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_bg.pdf)

español (ES) (69.53 KB - PDF)

**First published:**

28/02/2024

[View](/es/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (73.62 KB - PDF)

**First published:**

28/02/2024

[View](/cs/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (65.01 KB - PDF)

**First published:**

28/02/2024

[View](/da/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (88.48 KB - PDF)

**First published:**

28/02/2024

[View](/de/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (70.09 KB - PDF)

**First published:**

28/02/2024

[View](/et/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (79.55 KB - PDF)

**First published:**

28/02/2024

[View](/el/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_el.pdf)

français (FR) (64.19 KB - PDF)

**First published:**

28/02/2024

[View](/fr/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (81.81 KB - PDF)

**First published:**

28/02/2024

[View](/hr/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (71.71 KB - PDF)

**First published:**

28/02/2024

[View](/is/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (63.41 KB - PDF)

**First published:**

28/02/2024

[View](/it/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (81.19 KB - PDF)

**First published:**

28/02/2024

[View](/lv/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (83.18 KB - PDF)

**First published:**

28/02/2024

[View](/lt/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (78.66 KB - PDF)

**First published:**

28/02/2024

[View](/hu/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.28 KB - PDF)

**First published:**

28/02/2024

[View](/mt/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (70.04 KB - PDF)

**First published:**

28/02/2024

[View](/nl/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (71.75 KB - PDF)

**First published:**

28/02/2024

[View](/no/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_no.pdf)

polski (PL) (83.41 KB - PDF)

**First published:**

28/02/2024

[View](/pl/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_pl.pdf)

português (PT) (70.84 KB - PDF)

**First published:**

28/02/2024

[View](/pt/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_pt.pdf)

română (RO) (80.85 KB - PDF)

**First published:**

28/02/2024

[View](/ro/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (81.28 KB - PDF)

**First published:**

28/02/2024

[View](/sk/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (80.89 KB - PDF)

**First published:**

28/02/2024

[View](/sl/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (69.18 KB - PDF)

**First published:**

28/02/2024

[View](/fi/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (63.88 KB - PDF)

**First published:**

28/02/2024

[View](/sv/documents/all-authorised-presentations/casgevy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Casgevy Active substance Exagamglogene autotemcel International non-proprietary name (INN) or common name exagamglogene autotemcel Therapeutic area (MeSH)

- beta-Thalassemia
- Anemia, Sickle Cell

Anatomical therapeutic chemical (ATC) code B06AX05

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

β thalassemia

Casgevy is indicated for the treatment of transfusion dependent β thalassemia (TDT) in patients 12 years of age and older for whom haematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen (HLA) matched related HSC donor is not available.

Sickle cell disease

Casgevy is indicated for the treatment of severe sickle cell disease (SCD) in patients 12 years of age and older with recurrent vaso occlusive crises (VOCs) for whom haematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen (HLA) matched related HSC donor is not available.

## Authorisation details

EMA product number EMEA/H/C/005763

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Vertex Pharmaceuticals (Ireland) Limited

Unit 49, Block 5 Northwood Court Northwood Crescent Dublin 9 D09 T665 Ireland

Opinion adopted 14/12/2023 Marketing authorisation issued 09/02/2024 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Casgevy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (163.16 KB - PDF)

**First published:** 03/09/2025

[View](/en/documents/procedural-steps-after/casgevy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Casgevy : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (160.25 KB - PDF)

**First published:** 21/03/2024

**Last updated:** 03/09/2025

[View](/en/documents/procedural-steps-after/casgevy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Casgevy : Orphan maintenance assessment report (initial authorisation)

Reference Number: EMADOC-1700519818-1230857

English (EN) (497.67 KB - PDF)

**First published:** 28/02/2024

[View](/en/documents/orphan-maintenance-report/casgevy-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Casgevy : EPAR - Public assessment report

Adopted

Reference Number: EMA/6332/2024

English (EN) (3.74 MB - PDF)

**First published:** 28/02/2024

[View](/en/documents/assessment-report/casgevy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Casgevy

Adopted

Reference Number: EMA/CHMP/506425/2023

English (EN) (169.71 KB - PDF)

**First published:** 15/12/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-casgevy_en.pdf)

#### News on Casgevy

[First gene editing therapy to treat beta thalassemia and severe sickle cell disease](/en/news/first-gene-editing-therapy-treat-beta-thalassemia-and-severe-sickle-cell-disease) 15/12/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023) 15/12/2023

#### More information on Casgevy

- [EU/3/19/2210 - orphan designation for treatment of beta thalassaemia intermedia and major](/en/medicines/human/orphan-designations/eu-3-19-2210)
- [EU/3/19/2242 - orphan designation for treatment of sickle cell disease](/en/medicines/human/orphan-designations/eu-3-19-2242)
- [Healthcare Professional (HCP) Survey to Assess the Effectiveness of the Additional Risk Minimization Measures (aRMM) for Casgevy® (exagamglogene autotemcel) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000704)
- [Long-term registry-based study of patients with transfusion-dependent β-thalassemia (TDT) or sickle cell disease (SCD) treated with exagamglogene autotemcel (exa-cel) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000504)

**This page was last updated on** 03/09/2025

## Share this page

[Back to top](#main-content)